Erratum: MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer. Int J Cancer. 2014 May 15;134(10):2424-2436 doi: 10.1002/ijc.28566. Epub 2013 Nov 23.

  • Y. J. Kim
  • , H. S. Choi
  • , J. Seo
  • , J. Y. Song
  • , S. E. Lee
  • , M. J. Kwon
  • , M. J. Kwon
  • , J. Kundu
  • , K. Jung
  • , E. Oh
  • , Y. K. Shin
  • , Y. L. Choi

Research output: Contribution to journalComment/debate

Original languageEnglish
Pages (from-to)E6
JournalInternational Journal of Cancer
Volume135
Issue number7
DOIs
StatePublished - 1 Oct 2014

Cite this